| [1] |
GILL K, GHAZINIAN H, MANCH R, et al. Hepatitis C virus as a systemic disease: reaching beyond the liver[J]. Hepatol Int, 2016, 10(3): 415-423. DOI: 10.1007/s12072-015-9684-3. |
| [2] |
POZZATO G, MAZZARO C, DAL MASO L, et al. Hepatitis C virus and non-Hodgkin's lymphomas: Meta-analysis of epidemiology data and therapy options[J]. World J Hepatol, 2016, 8(2): 107-116. DOI: 10.4254/wjh.v8.i2.107. |
| [3] |
de SANJOSE S, BENAVENTE Y, VAJDIC CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium[J]. Clin Gastroenterol Hepatol, 2008, 6(4): 451-458. DOI: 10.1016/j.cgh.2008.02.011. |
| [4] |
GISBERT JP, GARCÍA-BUEY L, ARRANZ R, et al. The prevalence of hepatitis C virus infection in patients with non-Hodgkin's lymphoma[J]. Eur J Gastroenterol Hepatol, 2004, 16(2): 135-138. DOI: 10.1097/00042737-200402000-00003. |
| [5] |
PETRUZZIELLO A, MARIGLIANO S, LOQUERCIO G, et al. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes[J]. World J Gastroenterol, 2016, 22(34): 7824-7840. DOI: 10.3748/wjg.v22.i34.7824. |
| [6] |
CHENG Z, ZHOU B, SHI X, et al. Extrahepatic manifestations of chronic hepatitis C virus infection: 297 cases from a tertiary medical center in Beijing, China[J]. Chin Med J (Engl), 2014, 127(7): 1206-1210.
|
| [7] |
TASLEEM S, SOOD GK. Hepatitis C associated B-cell non-hodgkin lymphoma: clinical features and the role of antiviral therapy[J]. J Clin Transl Hepatol, 2015, 3(2): 134-139. DOI: 10.14218/JCTH.2015.00011. |
| [8] |
ZUCCA E, BERTONI F, VANNATA B, et al. Emerging role of infectious etiologies in the pathogenesis of marginal zone B-cell lymphomas[J]. Clin Cancer Res, 2014, 20(20): 5207-5216. DOI: 10.1158/1078-0432.CCR-14-0496. |
| [9] |
SULYOK M, MAKARA M, U'JHELYI E, et al. Non-Hodgkin lymphoma and hepatitis C: where we are and what next?[J]. Pathol Oncol Res, 2015, 21(1): 1-7. DOI: 10.1007/s12253-014-9845-z. |
| [10] |
VISCO C, FINOTTO S. Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment[J]. World J Gastroenterol, 2014, 20(32): 11054-11061. DOI: 10.3748/wjg.v20.i32.11054. |
| [11] |
COURONNÉ L, BACHY E, ROULLAND S, et al. From hepatitis C virus infection to B-cell lymphoma[J]. Ann Oncol, 2018, 29(1): 92-100. DOI: 10.1093/annonc/mdx635. |
| [12] |
PAYDAS S, KILIC B, YAVUZ S, et al. Anti-HCV and HCV-RNA prevalence and clinical correlations in cases with non-Hodgkin's lymphoma[J]. Am J Hematol, 2003, 74(2): 89-93. DOI: 10.1002/ajh.10386. |
| [13] |
VANNATA B, ARCAINI L, ZUCCA E. Hepatitis C virus-associated B-cell non-Hodgkin's lymphomas: what do we know?[J]. Ther Adv Hematol, 2016, 7(2): 94-107. DOI: 10.1177/2040620715623924. |
| [14] |
SAKAI H, MIWA T, IKOMA Y, et al. Development of diffuse large B-cell lymphoma after sofosbuvir-ledipasvir treatment for chronic hepatitis C: A case report and literature review[J]. Mol Clin Oncol, 2020, 13(3): 1. DOI: 10.3892/mco.2020.2071. |
| [15] |
POL S, VALLET-PICHARD A, HERMINE O. Extrahepatic cancers and chronic HCV infection[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(5): 283-290. DOI: 10.1038/nrgastro.2017.172. |
| [16] |
OCCHIPINTI V, FARINA L, VIGANÕ M, et al. Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma[J]. Dig Liver Dis, 2019, 51(5): 719-723. DOI: 10.1016/j.dld.2018.10.019. |
| [17] |
DEFRANCESCO I, ZERBI C, RATTOTTI S, et al. HCV infection and non-Hodgkin lymphomas: an evolving story[J]. Clin Exp Med, 2020, 20(3): 321-328. DOI: 10.1007/s10238-020-00615-6. |
| [18] |
SEHN LH, SALLES G. Diffuse large B-cell lymphoma[J]. N Engl J Med, 2021, 384(9): 842-858. DOI: 10.1056/NEJMra2027612. |
| [19] |
WANG L, LI LR, YOUNG KH. New agents and regimens for diffuse large B cell lymphoma[J]. J Hematol Oncol, 2020, 13(1): 175. DOI: 10.1186/s13045-020-01011-z. |
DownLoad: